Entries by

First Patients Treated in First-in-Human Trial for ACTISEAL® – Polyganics’ Innovative Liver and Pancreas Sealant Patch

15th September 2020 in /by

Groningen, The Netherlands, 15 September 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human study for ACTISEAL®, its Liver and Pancreas Sealant Patch. The ‘SHIELDS’ trial is a prospective, multicenter study, evaluating the safety and performance of ACTISEAL® in reducing […]

Polyganics Awarded €1.2 Million for Clinical Development of Liver and Pancreas Sealant Patch

13th May 2020 in /by

Groningen, The Netherlands, 13 May 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has received EUR 1.2 million in funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen, to support clinical validation […]

Polyganics Announces Start Building New Facility

3rd March 2020 in /by

Groningen, The Netherlands, 3 March 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced the ground-breaking of a new facility at the Zernike Campus, Groningen. Polyganics aims to move into its new facility, which will house its headquarters, state-of-the-art research laboratories and expanded manufacturing and packaging facilities, in 2021. […]

Polyganics Achieves CE Mark Certification for LIQOSEAL®

7th January 2020 in /by

Groningen, The Netherlands, 07 January 2020 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, announced today that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch, and will launch the device in Europe with immediate effect. Approval of the CE mark is based on outstanding […]

Polyganics Achieves Positive 3-month Follow-up Data of ENCASE I, the First Clinical Trial for LIQOSEAL®

17th September 2019 in /by

Groningen, The Netherlands, 17 September 2019 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, has today announced positive data from its ENCASE I* clinical trial. The ENCASE I trial is focused on the evaluation of the safety and performance of LIQOSEAL® in reducing cerebrospinal fluid (CSF) leakage following elective cranial […]

Polyganics Builds New Facility to Continue Growth, Supported by RIG Subsidy of €3.8 Million

10th April 2019 in /by

Groningen, The Netherlands, 10 April 2019 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, is expanding its capacity with a new facility at the Zernike Campus, Groningen, to enter a new phase of commercial and R&D growth. Polyganics has been awarded a subsidy of €3.8 million by the Regional Investment […]